URG101 Pharmacodynamic and Safety Study: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Cross-Over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.

Trial Profile

URG101 Pharmacodynamic and Safety Study: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Cross-Over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2015

At a glance

  • Drugs Heparin/lidocaine/sodium-bicarbonate (Primary) ; Heparin; Lidocaine
  • Indications Bladder disorders; Interstitial cystitis; Pain
  • Focus Therapeutic Use
  • Sponsors Urigen
  • Most Recent Events

    • 18 May 2015 Results presented at the Canadian Journal of Urology, as reported by Imprimis Pharmaceuticals media release.
    • 08 Apr 2008 Final analysis will be reported later in quarter 2, 2008.
    • 08 Apr 2008 This trial has been closed early due to positive interim results, so that continuing enrolment would not meaningfully alter the study conclusions, according to a Urigen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top